MSB announced an addition to their BOD.  He is the Chief Strategy officer of SurgiCenter is one of the largest private operators of ambulatory surgical centers (ASC) in the US specializing in spine, orthopaedic and total joint procedures. Theprincipals of SurgCenter were the lead investors in Mesoblast’s successful US$110 million private placement, completed earlier this month.   He said, "My fellow principals at SurgCenter and I are very excited about the future potential for Mesoblast across the breadth of its platfo rm technology from chronic heart failure and inflammatory bowel disease to the potential treatment for chronic low back pain. I welcome the opportunity to make a significant contribution to the success in bringing these potential treatments to market and look for ward to working with the Board and management team.” 

This is the area MSB needs the most help as they have yet to clear any FDA hurdle placed before them.  This new investor believes in numerous therapies MSB has to offer and hopefully can bring the necessary skills to get them to market.  As a long time holder, I sure hope so.